Senseonics Holdings, Inc.
SENSHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeSenseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the. The company carries a $493.3M market cap, placing it firmly in the small-cap category. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
Market Cap
$493.3M
Beta
1.08
P/E (TTM)
—
P/E (Fwd)
-4.79
EPS (TTM)
$-2.24
EPS (Fwd)
$-1.95
ROE
-118.2%
ROA
-41.4%
Cash
$142.7M
Total Debt
$62.8M
Free CF
-$59.2M
52W Change
9.9%
Annual Financials
Cash vs Debt
Where SENS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SENS finished 49.03% above its 150-day moving average ($6.67) and 50.15% above its 200-day moving average ($6.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SENS overbought or oversold?
At the September 3, 2026 close, SENS's RSI(14) was 76.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Senseonics Holdings, Inc. holds $142.7M in cash against $62.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$59.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -118.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $16.4M (2022) to $35.3M (2025), reflecting a 115% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing SENS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.